COVID-19 in early 2021: current status and looking forward.
COVID-19 in early 2021: current status and looking forward.
复制标题
DOI：
10.1038/s41392-021-00527-1
复制
发表时间：
2021-03-08
影响因子：
39.3
通讯作者：
Li W
中科院分区：
文献类型：
--
作者：
Wang C;Wang Z;Wang G;Lau JY;Zhang K;Li W
自2019年12月首次描述与冠状病毒相关的肺炎疫情以来，导致这种感染/疾病（COVID-19）的SARS-CoV-2病毒已演变成一场大流行，截至今天，全球210多个国家的100亿人已被确认感染，200万人已死于COVID-19。这篇简短的综述总结了我们迄今为止在以下领域了解到的情况：流行病学、病毒学和发病机制、诊断、人工智能在辅助诊断、治疗和疫苗开发中的应用。由于在这些领域中有许多并行的开发，并且一些开发和部署以前所未有的速度进行，我们还提供了某些开发和里程碑的具体日期，以便读者能够了解这些关键事件的时间安排。值得注意的是，在病毒被发现后的一年内，有诊断方法、抗病毒药物和疫苗被监管机构开发并批准。由于许多发展是并行进行的，我们还提供了一些关键事件的具体日期，以便读者能够了解这些研究数据的演变和我们的理解。全世界正在共同努力抗击这一流行病。本文还重点介绍了这些领域在不久的将来将迅速发展的研究和发展方向。
Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a pandemic, and as of today, >100 million people globally in over 210 countries have been confirmed to have been infected and two million people have died of COVID-19. This brief review summarized what we have hitherto learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development. As there are a number of parallel developments in each of these areas and some of the development and deployment were at unprecedented speed, we also provided some specific dates for certain development and milestones so that the readers can appreciate the timing of some of these critical events. Of note is the fact that there are diagnostics, antiviral drugs, and vaccines developed and approved by a regulatory within 1 year after the virus was discovered. As a number of developments were conducted in parallel, we also provided the specific dates of a number of critical events so that readers can appreciate the evolution of these research data and our understanding. The world is working together to combat this pandemic. This review also highlights the research and development directions in these areas that will evolve rapidly in the near future.
登录
查看更多内容
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
168.9
作者：
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者：
Yuen, Kwok-Yung
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
168.9
作者：
Chen, Huijun;Guo, Juanjuan;Zhang, Yuanzhen
通讯作者：
Zhang, Yuanzhen
DOI：
10.15585/mmwr.mm6912e2
发表时间：
2020-03-27
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
CDC COVID-19 Response Team
通讯作者：
CDC COVID-19 Response Team